Form 4: Recursion Pharmaceuticals Director Blake Borgeson Sells Shares Under 10b5-1 Plan

Director Blake Borgeson sold shares of Recursion Pharmaceuticals under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On April 16, 2024, Blake Borgeson, a director at Recursion Pharmaceuticals, sold 11,447 shares of Class A Common Stock.
• The sale was executed at a weighted average price of $7.6636 per share, with individual trades ranging from $7.54 to $7.77.
• The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on August 18, 2023.
• Following the transaction, Borgeson directly owns 7,229,861 shares of Recursion Pharmaceuticals.
• The sale was reported on Form 4, filed with the Securities and Exchange Commission on April 18, 2024.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it reports a routine stock sale under a pre-arranged trading plan. It doesn't inherently indicate positive or negative sentiment towards the company.

Industry Context

This is a routine disclosure of an insider stock sale. It's common for executives and directors to use 10b5-1 plans to sell shares over time to avoid accusations of insider trading. The sale itself doesn't necessarily indicate a negative outlook on the company.

Stakeholder Impact

• The stock sale could have a minor negative impact on shareholder sentiment, but is unlikely to have a significant impact given the pre-planned nature of the sale.

Key Dates